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Ascorbate requiring Fe2+/2-oxoglutarate-dependent dioxygenases located in the nucleoplasm have been shown to participate in
epigenetic regulation of gene expression via histone and DNA demethylation. Transport of dehydroascorbic acid is impaired in
the endomembranes of ﬁbroblasts from arterial tortuosity syndrome (ATS) patients, due to the mutation in the gene coding for
glucose transporter GLUT10. We hypothesized that altered nuclear ascorbate concentration might be present in ATS ﬁbroblasts,
aﬀecting dioxygenase activity and DNA demethylation. Therefore, our aim was to characterize the subcellular distribution of
vitamin C, the global and site-speciﬁc changes in 5-methylcytosine and 5-hydroxymethylcytosine levels, and the eﬀect of
ascorbate supplementation in control and ATS ﬁbroblast cultures. Diminished nuclear accumulation of ascorbate was found in
ATS ﬁbroblasts upon ascorbate or dehydroascorbic acid addition. Analyzing DNA samples of cultured ﬁbroblasts from controls
and ATS patients, a lower global 5-hydroxymethylcytosine level was found in ATS ﬁbroblasts, which could not be signiﬁcantly
modiﬁed by ascorbate addition. Investigation of the (hydroxy)methylation status of speciﬁc regions in six candidate genes
related to ascorbate metabolism and function showed that ascorbate addition could stimulate hydroxymethylation and active
DNA demethylation at the PPAR-γ gene region in control ﬁbroblasts only. The altered DNA hydroxymethylation patterns in
patient cells both at the global level and at speciﬁc gene regions accompanied with decreased nuclear accumulation of ascorbate
suggests the epigenetic role of vitamin C in the pathomechanism of ATS. The present ﬁndings represent the ﬁrst example for
the role of vitamin C transport in epigenetic regulation suggesting that ATS is a compartmentalization disease.
1. Introduction
Beyond its antioxidant properties, ascorbic acid (AA)
[1]—the reduced form of vitamin C—is required for the
proper functioning of several enzymes, including Fe2+/2--
oxoglutarate-dependent dioxygenases [2] present in various
subcellular compartments. Fe2+/2-oxoglutarate-dependent
dioxygenases catalyze diverse oxidative reactions including
the posttranslational modiﬁcation of proteins in the
endoplasmic reticulum (ER) and demethylations related to
epigenetic regulation in the nucleus. Nucleoplasmic
JmjC-domain-containing demethylases [3] and TET
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(ten-eleven translocation) methylcytosine dioxygenases [4]
promote the demethylation of histones and DNA, respec-
tively, both mechanisms being involved in the epigenetic
regulation of transcription [5]. 5-Methylcytosine (5-mC)
demethylation occurs via consecutive oxidative steps
catalyzed by the TET dioxygenases through a
5-hydroxymethylcytosine (5-hmC) intermediate [6].
To ensure the AA supply of these AA-dependent
enzymes in various subcellular compartments, transporters
are needed in the membrane of organelles. In general terms,
AA transport is mediated by sodium-dependent transporters,
while its oxidized form dehydroascorbic acid (DHA) is trans-
ported by GLUT family transporters [7, 8]. However, the
occurrence and functioning of these transporters have been
hardly elucidated in the endomembranes [9].
Arterial tortuosity syndrome (ATS, OMIM #208050) is a
monogenic autosomal recessive connective tissue disorder
characterized by elongation and generalized tortuosity of
the major arteries. ATS is caused by the loss-of-function
mutations in SLC2A10 gene encoding GLUT10 protein, a
member of the glucose transporter family GLUT [10–14].
However, the exact role of GLUT10 in the ATS pathogenesis
remains still debated. The perinuclear location of GLUT10
was reported in ﬁbroblasts [12], which has been conﬁrmed
by forthcoming studies [15, 16]. These observations raised
the possibility that the compromised transport of glucose
into the nucleoplasm can be responsible for the pathogenesis
[12]. However, recently we demonstrated that GLUT10
functions as a DHA transporter, carrying the oxidized form
of vitamin C through the perinuclear membrane. This
was proven by measuring the transport activity of
in vitro-translated GLUT10 protein incorporated in lipo-
somes and by detecting a diminished DHA uptake
through the endomembrane system of ﬁbroblasts derived
from ATS patients [17].
Based on the abovementioned ﬁndings, we hypothe-
sized that the activity of nucleoplasmic Fe2+/2--
oxoglutarate-dependent dioxygenases is lower in the ATS
patients’ ﬁbroblasts due to the diminished transport of
DHA and the consequent impoverishment of the nucleo-
plasm in the vitamin. Thus, experiments were undertaken
to investigate the subcellular distribution of AA and DHA
and the possible DNA (hydroxy)methylation alterations in
ﬁbroblasts derived from ATS patients. According to our
assumption, decreased nuclear accumulation of AA and
altered DNA hydroxymethylation patterns at both the
global level and at speciﬁc gene regions were found in
patients’ ﬁbroblasts, which suggests the epigenetic role of
vitamin C in the pathomechanism of ATS.
2. Materials and Methods
2.1. Cell Cultures. Skin ﬁbroblasts from four ATS patients
and four healthy donors were established from skin biopsies
as previously reported [12]. Patients were either homozygous
for the c.1411+1G>A splicing mutation [11] or were bearing
the homozygous c.510G>A mutation [12]. Three additional
skin ﬁbroblast primary culture samples from control subjects
were obtained at the Institute of Genomic Medicine and Rare
Disorders, Semmelweis University (Budapest, Hungary).
One postmortem dermis tissue was also used (from the 2nd
Department of Pathology, Semmelweis University). The
study was approved by the medical ethical committee of the
University Hospital Spedali Civili of Brescia, Italy, the Ghent
University Hospital, Belgium, and the Semmelweis Univer-
sity and was performed in accordance with the Declaration
of Helsinki Principles.
Fibroblast cells were cultured in Dulbecco’s Modiﬁed
Eagle Medium supplemented with 10% fetal bovine serum,
1% penicillin-streptomycin, and 1% minimum essential
medium nonessential amino acids (Life Technologies, Carls-
bad, CA, USA). Cell cultures were grown in vitro at 37°C and
in a 95% air and 5% CO2 atmosphere. Cells were preincu-
bated with 50μM of AA (ﬁnal concentration) for 24 hours
before harvesting them. Cells were analysed at the same
in vitro passage number (5th to 7th).
2.2. Cell Treatment. Fibroblasts were treated with AA or
DHA as indicated. DHA is an unstable compound at physio-
logic pH and temperature, with a half-life of minutes; via
hydrolysis of the lactone ring, it is irreversibly converted to
2,3-diketo-1-gulonic acid [18]. Thus, the addition of DHA
cannot ensure a stable, prolonged extracellular concentration
of the compound. Therefore, with the exception of certain
short-term experiments, AA was added to the cells. Accord-
ing to present knowledge, the transportable form of the mol-
ecule within the cell is DHA, as endomembranes do not
possess AA transporters [9, 7] and oxidation of AA greatly
enhances the transport across the ER membrane [19].
Since AA-dependent reactions—essentially present in all
cellular compartments—lead to the direct or consequen-
tial formation of DHA within the cell, DHA transport
through the endomembranes becomes possible. Due to
these reasons, subcellular distribution of AA and the eﬃ-
ciency of AA-dependent reactions mainly reﬂect the
extent of intracellular DHA transport. Because of the lat-
ter reason and of the instability of DHA, AA was used in
our long-term experiments.
2.3. Transmission Electron Microscopy and Immunoelectron
Microscopy. Transmission electron microscopy was per-
formed as previously described [20]. After pretreatment of
the cells with either 50μM (ﬁnal concentration) of AA or
DHA for 5min, the media were removed from conﬂuent cell
cultures, cells were washed with phosphate-buﬀered saline
(PBS), and trypsin was then added to make the cells detach
from the bottom of the ﬂask. After ﬁve minutes of incubation
at 37°C, the reaction was stopped with a trypsin inhibitor.
Then, cells were resuspended in PBS, washed brieﬂy, and
collected by centrifuge. Pellets were ﬁxed in 3.2% paraformal-
dehyde, 0.5% glutaraldehyde, 1% sucrose, and 0.028% CaCl2
in 0.1M sodium cacodylate, pH7.4, overnight at 4°C, and
embedded into London Resin Gold (Agar Scientiﬁc, UK)
without postﬁxation according to the manufacturer’s
recommendations.
Ultrathin sections (90 nm) were collected on nickel grids
and incubated with rat polyclonal antibody to conjugated
Vitamin C (Abcam) (1 : 25) in PBS with 3% milk overnight
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at 4°C followed by 18nm Colloidal Gold-AﬃniPure Goat
Anti-Rat IgG (1 : 15; Jackson ImmunoResearch Laboratories
Inc.) for 5 hours in TBS with 1.5% milk and 0.25% Tween
20 at 4°C.
Immunolabelled sections were contrasted with uranyl
acetate and Reynold’s lead citrate and viewed on a transmis-
sion electron microscope (JEOL JEM-1011) operating at
60 kV. Electron micrographs were taken with a CCD camera
(Morada; Olympus) and iTEM software (Olympus). A total
of 15 randomly taken 25,000x magniﬁcation images of sec-
tions from four control and four ATS patient cell culture
samples were evaluated by manually encircling relevant
structures in ImageJ (NIH) and calculating their percentage
of area relative to total cytoplasm. The distributions of gold
particles over relevant structures were also counted. P values
were calculated with Mann–Whitney’s U test for pairwise
comparison of nonnormal distribution data and nonpara-
metric Kruskal-Wallis tests for multiple comparisons of non-
normal distribution data [21].
2.4. DNA Samples. Genomic DNA was isolated using the
Blood & Cell Culture DNAMini Kit (cat. No. 13323, Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions. The dsDNA samples were initially quantiﬁed using a
NanoDrop spectrophotometer (Thermo Fisher Scientiﬁc
Inc., Waltham, MA, USA) and normalized to 40 ng/μl in
TE buﬀer. Fragmentation was carried out in 0.25ml of
40 ng/μl stock DNA placed in 1.5ml Eppendorf tubes
immersed in an ice-water bath and sonicated for 6× 30 sec
by a Model 300 Sonic Dismembrator (Artek Systems Corp.,
Farmingdale, NY, USA). The evaluation of the size range of
the fragmented DNA was performed by electrophoresis
using a 1.5% agarose gel in TAE buﬀer (0.1M Tris–HCl
pH8, 0.083M acetic acid, 1mM EDTA, and 0.5mg/ml
ethidium bromide).
2.5. Measurements of Global 5-Methylcytosine and
5-Hydroxymethylcytosine Levels in the Genome. Global levels
of 5-mC and 5-hmC were assessed by MethylFlash Color-
imetric DNA Quantiﬁcation Kits from EpiGentek (cat. No.
P-1030-48 and P-1032-48, Farmingdale, NY, USA). In
these assays, genomic DNA was bound to speciﬁcally
treated wells to have a high DNA aﬃnity. The (hydroxy)-
methylated DNA fragments were detected with capture
and detection antibodies following the company’s protocol
and quantiﬁed by reading the absorbance in a microplate
spectrophotometer (Multiskan Spektrum, Thermo Fisher
Scientiﬁc Inc., Waltham, MA, USA) at 450nm. Liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
was carried out using a previously published protocol
[22] after hydrolyzing the genomic DNA to nucleobases
with formic acid [23]. Brieﬂy, 100μl of formic acid (100%)
was added to 20μl of 40ng/μl DNA sample and pipetted into
a 2ml glass vial. The tightly crimped vial was kept at 130°C
for 90min. After nitrogen evaporation, the samples were
reconstituted in acetonitrile solution containing 0.1% formic
acid. Chemical standards dCTP, 5mdCTP, and 5hmdCTP
were used to optimize the mass spectrometer (Sciex 6500
Qtrap System, Sciex, Redwood City, CA, USA). Separation
was performed with a PerkinElmer Series 200 system (Perki-
nElmer, Waltham, MA, USA).
2.6. Selection of Candidate Gene Regions for
Hydroxymethylation Status Analysis. Quantitative 5-mC-
and 5-hmC-enrichment analyses were carried out on candi-
date genes coding for proteins involved in the metabolism
or function of AA or described to be related to ATS. The
selected genes were P3H1 (prolyl 3-hydroxylase 1), P4HA1
(prolyl 4-hydroxylase, alpha 1 subunit), P4HA2 (prolyl
4-hydroxylase alpha 2 subunit), PLOD1 (lysyl hydroxylase),
ALDH1A1 (aldehyde dehydrogenase 1 family, member A1),
and PPAR-γ (peroxisome proliferator-activated receptor
gamma). Within these genes, speciﬁc regions were chosen
for analyses based on highly modiﬁed cytosine levels in
K562, HUVEC, HepG2, H1hESC, and Hela-S3 cell lines
according to epigenome-wide data (e.g., Inﬁnium Human-
Methylation 450K microarray or reduced representation
bisulﬁte sequencing), and H3K27 acetylation signal using
ENCODE data shown in the UCSC Genome Browser [24].
Since 5-hmC is most abundant at both poised and active
enhancers [25], we selected potentially active enhancer
regions using H3K4 methylation and H3K27 acetylation
marks [26]. In addition to the abovementioned genes, the
GAPDH promoter was used as a negative control to check
the lack of enrichment in the bound samples. PFKFB3
(6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3)
was included as a positive control based on the
5-hmC-sequencing signal of 3 publicly available datasets
derived from cells of mesoderm origin (GSE64393,
GSE49291, and GSE59989).
2.7. Measurements of Locus-Speciﬁc DNA Modiﬁcation Level
Changes after Ascorbate Treatment.Methylated DNA immu-
noprecipitation (MeDIP) was performed with
Anti-5-Methylcytidine antibody (cat. No. BI-MECY-0500,
Eurogentec, Liège, Belgium) using a previously established
protocol [27] with a few technical changes. Shortly, 2μg
(50μl of 40ng/μl conc.) of sonicated genomic DNA
(input) was diluted to 100μl. A preclear step was per-
formed with 30μl of Protein A/G (cat. No. 88803, Thermo
Fisher Scientiﬁc Inc., Waltham, MA, USA) for 1 hour at
4°C on a rotator. Immunoprecipitation was carried out
with 4μl of anti-5mC antibody. After the DNA-antibody
incubation, 50μl of protein A/G was added to the tubes
and incubated with the DNA-antibody mixture for 2
hours at 4°C. The beads were washed three times with
0.5mL of IP buﬀer (0.14M NaCl, 0.05% Triton X-100 in
10mM PBS, pH7), and then treated with proteinase K at
55°C overnight to elute the immunoprecipitated DNA
(bound fraction), which was further puriﬁed with
phenol-chloroform. Ampliﬁcation of the input and MeDIP
bound fractions was carried out with a GenomePlex Com-
plete Whole Genome Ampliﬁcation Kit (cat. No. WGA-2,
Sigma-Aldrich, St. Louis, MO, USA) in order to carry out
multiple reactions of gene-speciﬁc analyses.
Hydroxymethylated DNA immunoprecipitation (hMe-
DIP) was carried out with the Hydroxymethyl Collector Kit
(cat. No. 55013, Active Motif, La Hulpe, Belgium) using
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1.5μg of genomic DNA according to the manufacturer’s
instructions. Since the DNA yield in the hMeDIP bound
samples was in the picogram range, the DNA concentra-
tion was determined with the QuantiFluor dsDNA Sys-
tem (Promega, Madison, WI, USA) on the Quantus
Fluorometer (Promega, Madison, WI, USA). For the
ampliﬁcation, 30 pg of the hMeDIP bound fractions
was used with the PicoPLEX WGA Kit (cat. No.
E2620L, New England BioLabs Inc., Hitchin, Hertford-
shire, UK). The WGA samples were puriﬁed with a
GeneJET PCR Puriﬁcation Kit (cat. No. K0702, Thermo
Fisher Scientiﬁc Inc., Waltham, MA USA), measured
with a NanoDrop spectrophotometer and diluted to
10 ng/μl ﬁnal concentration for qPCR.
Quantitative analyses of 5-mC and 5-hmC enrichment were
carried out at speciﬁc regions of candidate genes. For
region-speciﬁc primer pairs, see Table S1. The gene
region-speciﬁc real-time PCR was performed on the ampliﬁed
input and bound fractions using 20ng of DNA per reaction
and the PowerUp SYBR Green Master Mix (cat. No. A25742,
Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA) in 15μl
volume on a QuantStudio 12K Flex Real-Time PCR System
(Thermo Fisher Scientiﬁc Inc.). To determine the relative
DNA enrichment, the comparative 2−ΔΔCt method was used
with postmortem dermis tissue as the reference sample (the
ﬁrst ΔCt was calculated from the diﬀerence of threshold cycle
values of the Bound − Input samples).
2.8. Quantiﬁcation of 5-Methylcytosine and
5-Hydroxymethylcytosine Level at a Speciﬁc CCGG Site.
Locus-speciﬁc analysis was performed with the EpiMark
5-hmC and 5-mC Analysis Kit (cat. No. E3317S, New
England BioLabs Inc., Hitchin, Hertfordshire, UK) according
to the manufacturer’s instructions. Brieﬂy, DNA samples
(5μg) were mixed with 31μl of 1x NEBuﬀer4 and 12.4μl of
UDP-Glucose (ﬁnal concentration 80μM). This mixture
was split into two, and 30units (3μl) of T4 β-glycosyltrans-
ferase was added to one of the tubes (the other tube served
as a control reaction); both tubes were incubated at 37°C
for 18 hours. After incubation, each reaction mixture was ali-
quoted into three tubes, labelled 1-3 of the T4 β-glycosyl-
transferase treatment, and 4-6 of the control reaction. The
following restriction enzymes were added to the tubes:
100U of MspI (can cleave if the internal C is 5-mC or
5-hmC but cannot cleave the glycosylated 5-hmC) was added
to tubes 1 and 4 and 50U of HpaII (can cleave only nonmo-
diﬁed C sequence) was added to tubes 2 and 5. No restriction
enzymes were added to tubes 3 and 6 since they served as
controls. Samples were incubated at 37°C for 8 hours. After-
wards, 20μg of proteinase K was added to each tube (ﬁnal
volume 53μl) and incubated at 40°C for 30 minutes. Finally,
proteinase K was inactivated by incubating at 95°C for 10
minutes. The gene region-speciﬁc real-time PCR was per-
formed using 2μl of each reaction mixture (~30ng of DNA
from tubes 1 to 6) in duplicates using the same PPAR-γ
primers as described previously. The relative proportions of
methylated and hydroxymethylated gene regions were calcu-
lated according to the formula provided by the manufacturer.
3. Results
3.1. Nuclear Accumulation of Ascorbate Diminished in ATS
Fibroblasts.While compartmentalization of AA is well estab-
lished in plants, the compartment-speciﬁc levels of the vita-
min are still unclear in mammalian cells. A previously
developed method in plants based on high-resolution immu-
noelectron microscopy [28] was applied here to directly eval-
uate and simultaneously quantify subcellular AA levels. First,
the subcellular distribution of AA was investigated in human
ﬁbroblasts isolated from healthy controls. As the basal AA
level of human cells is far behind the AA content of plant
cells, AA pretreatment of ﬁbroblasts was applied to reach
the detection level of the vitamin. In order to compare a pos-
sible diﬀerence in the uptake of the reduced and oxidized
form of the vitamin, we applied both AA and DHA pretreat-
ments. In both cases, similar and signiﬁcant cellular accumu-
lation of the vitamin was observed, eminently in the nucleus
(Figure 1(a)). Nuclear AA level was signiﬁcantly higher than
that of the cytosol (Figure 1(b)), which implies the transport
and consequent accumulation of the vitamin in the compart-
ment. Gold particles indicating AA level in ER, mitochon-
dria, and other smaller compartments were less abundant
and hardly quantiﬁable separately.
In a second set of experiments, AA levels of cytoplasm
and nucleus were compared in control and ATS ﬁbroblasts
in a similar experimental setup (Figure 2(a)). We found a sig-
niﬁcantly lower nucleoplasmic/cytoplasmic ratio of AA in
ﬁbroblasts derived from ATS patients, indicating that defec-
tive transport to the nucleus indeed diminished nuclear AA
levels (Figure 2(b)).
3.2. Global 5-Methylcytosine and 5-Hydroxymethylcytosine
Levels in the Genome of Cultured Fibroblasts. To examine
whether GLUT10-deﬁcient ATS ﬁbroblasts possess any
alteration at the epigenetic level due to defective nuclear
DHA transport, we compared global levels of cytosine
methylation and hydroxymethylation in cultured ﬁbro-
blasts derived from controls and ATS patients. 5-mC and
5-hmC levels were compared before and after the addition
of AA, which is expected to stimulate TET
enzyme-mediated 5-mC-5-hmC conversion only in control
cells. First, we used speciﬁc ELISA kits (Figures 3(a) and
3(c)), then we used liquid chromatography-tandem mass
spectrometry (LC-MS/MS, Figures 3(b) and 3(d)). Analysis
of the global DNA methylation level revealed no signiﬁ-
cant diﬀerences between ATS patients and controls
(Figures 3(a) and 3(b)). In the control samples, AA treat-
ment decreased the 5-mC level when measured by ELISA
(p = 0 020); however, this result was not conﬁrmed in the
LC-MS/MS measurement. In the case of global DNA
hydroxymethylation levels, ELISA measurement yielded
quite low levels of 5-hmC (Figure 3(c)), showing that the
kit was possibly not sensitive at this range of 5-hmC.
The LC-MS/MS measurement yielded a more detailed pic-
ture (Figure 3(d)): hydroxymethylation levels in the
genome of ATS ﬁbroblasts were lower than that of con-
trols (p = 0 027). Global 5-hmC levels (5-hmC/C ratios)
were increased after AA treatment in both groups, but this
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increase was statistically signiﬁcant only in the control
group (p = 0 047).
3.3. Gene Region-Speciﬁc Cytosine Modiﬁcations. DNA
immunoprecipitation speciﬁcally designed to enrich 5-mC-
and 5-hmC-containing regions were combined with quanti-
tative PCR ampliﬁcation of the bound and input fractions
to analyse region-speciﬁc cytosine modiﬁcations. The relative
enrichment of the bound fractions of the ﬁbroblast samples
was compared to the control (postmortem) dermis tissue’s
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Figure 1: Subcellular distribution of ascorbate in human ﬁbroblasts. Subcellular distribution of ascorbate in human ﬁbroblasts derived from
healthy controls (n = 4) was assessed by immunoelectron microscopy. After pretreatment of ascorbate or dehydroascorbic acid, cells were
ﬁxed and labeled with an antibody raised against ascorbate and analyzed following immunogold staining. (a) A representative image of
the electron microscopy is shown. Scale bar is 1μm. N: nucleus, Nu: nucleolus. (b) Distribution of gold particles—representing
ascorbate—was determined with respect to the relative area of the cytosol or the nucleus. A signiﬁcantly higher level of the vitamin was
observed in the nucleus compared to cytosol after both ascorbate and dehydroascorbate treatment. Data are means ± SEM, ∗∗∗p < 0 001,
∗∗p < 0 01.
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Figure 2: Diminished nuclear accumulation of vitamin C in ATS ﬁbroblasts. Subcellular distribution of ascorbate of human ﬁbroblasts
derived from healthy controls or arterial tortuosity syndrome patients were compared by immunoelectron microscopy. After pretreatment
of dehydroascorbic acid, cells were ﬁxed and labeled with ascorbate antibody, and analyzed by following immunogold staining. (a)
Representative images of the electron microscopy are shown from control (upper panel) and arterial tortuosity syndrome patient (lower
panel) samples. Scale bar is 1μm. N: nucleus, Nu: nucleolus. (b) Nuclear/cytoplasmic ratio of immunogold particles—representing
ascorbate—was assessed. A signiﬁcantly lower level of nucleus/cytoplasm ascorbate ratio was found after dehydroascorbate treatment in
ﬁbroblasts derived from arterial tortuosity syndrome patients compared to control ﬁbroblasts (4 in each groups). Data are means ± SEM,
∗∗p < 0 01.
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values. At the majority of the examined gene regions,
decreased 5-hmC levels were observed in cultured ﬁbroblasts
derived from either controls or patients as compared to the
tissue level, which is in line with previous observations [29],
but this decrease could be reversed by ascorbate treatment
(Table S1). Due to the limited number of patients and the
high variability of the qPCR values, these changes were
signiﬁcant only in one gene. In the case of PPAR-γ, we
observed a signiﬁcantly higher 5-hmC level in the control
group after AA treatment compared to untreated control
samples (Figure 4(b)). AA treatment of ﬁbroblasts derived
from ATS patients had no eﬀect on the 5-hmC level. A
similar reversal of the 5-hmC level after AA treatment was
observed at the 5-hmC-control region in the PFKFB3 gene
(Table S1). Furthermore, AA treatment signiﬁcantly
decreased the 5-mC level of the selected region in PPAR-γ
only in control ﬁbroblasts, potentially indicating increased
active demethylation processes (Figure 4(a)).
To reinforce this result, we carried out another
locus-speciﬁc measurement on the same PPAR-γ gene region
using the EpiMark 5-hmC and 5-mC Analysis Kit. This
restriction enzyme-based technique distinguishes 5-mC from
5-hmC by the glycosylation of the hydroxyl group of 5-hmC.
When the internal C of a CCGG sequence is modiﬁed, the
glycosylation of 5-hmC changes the MspI cleavage site into
a noncleavable one (for details, see Materials and Methods).
The AA treatment decreased 5-mC levels (p = 0 029) and
increased 5-hmC levels (p = 0 026) in control ﬁbroblast sam-
ples, while methylation and hydroxymethylation status in
ATS patient ﬁbroblasts did not change signiﬁcantly
(Figure 5).
4. Discussion
The presented results demonstrate that the intracellular com-
partmentalization of vitamin C can be an important factor in
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Figure 3: Global 5-methylcytosine and 5-hydroxymethylcytosine levels in the genome of ﬁbroblasts derived from healthy controls and
arterial tortuosity syndrome patients; 5-methylcytosine (5-mC) levels of ﬁbroblasts derived from controls and arterial tortuosity syndrome
patients, with or without ascorbate (AA) supplementation, measured with MethylFlash ELISA Colorimetric DNA kit (a) or with
liquid chromatography-tandem mass spectrometry (LC-MS/MS, (b)). 5-Hydroxymethylcytosine (5-hmC) levels of control and patient
ﬁbroblasts, with or without AA supplementation, measured with ELISA kit (c) or LC-MS/MS (d). Data are presented as means ± SE
M, n = 3-7, ∗p < 0 05.
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epigenetic regulation. We used ATS ﬁbroblasts as a model
system: ATS is a genetic disease due to the mutations in
SLC2A10 gene, encoding GLUT10, a glucose/DHA trans-
porter of the endomembranes. As we previously reported,
intracellular DHA transport was impaired in these cells
[17]. In the present study, we demonstrate that in ATS ﬁbro-
blasts (i) DNAmethylation cannot be decreased by AA addi-
tion (while in control ﬁbroblasts, it can be); (ii) the
hydroxymethylation level is lower than in control cells; (iii)
unlike in control ﬁbroblasts, the hydroxymethylation level
cannot be signiﬁcantly increased by AA addition; (iv)
decreased hydroxymethylation of a speciﬁc gene region in
PPAR-γ gene is present; and (v) AA addition cannot stimu-
late 5-mC-to-5-hmC conversion in the PPAR-γ gene unlike
in control ﬁbroblasts.
In our ﬁrst exploratory experiment, the nucleoplasmic
occurrence of vitamin C was checked. Hitherto, the presence
of vitamin C in the nucleus has not been directly measured in
living animal cells. By using immunogold labelling and trans-
mission electron microscopy, a technique successfully
applied in plant cells [28], we veriﬁed that vitamin C
appeared and accumulated in the nucleus of control ﬁbro-
blasts upon AA or DHA addition within 5 minutes. When
nuclear vitamin C uptake was compared in control and
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Figure 4: Gene region-speciﬁc cytosine modiﬁcations in peroxisome proliferator-activated receptor gamma gene using DNA
immunoprecipitation enrichment. DNA immunoprecipitation was combined with quantitative PCR ampliﬁcation (Q-MeDIP: (a),
Q-hMeDIP: (b)) to analyse region-speciﬁc cytosine modiﬁcations in the selected gene region. The relative enrichment of the bound
fractions of ﬁbroblast DNA samples was compared to a control dermis tissue DNA sample. Data are means ± SEM, n = 3-7, ∗p < 0 05.
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Figure 5: Gene region-speciﬁc cytosine modiﬁcations in peroxisome proliferator-activated receptor gamma gene using diﬀerential restriction
endonuclease cleavage. The EpiMark 5-hmC and 5-mC Analysis Kit uses a glycosylation pretreatment to distinguish 5-hmC from 5-mC via
diﬀerential restriction endonuclease digestion of a CCGG sequence. The relative ratios (percentage of 5-mC, 5-hmC, and non-modiﬁed C) are
quantiﬁed using quantitative PCR ampliﬁcation. Average values ± SEM of modiﬁed C % are shown for controls ((a), n = 6) and patients ((b),
n = 3), ∗p < 0 05.
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ATS ﬁbroblasts, we observed a signiﬁcantly lower ratio of
nucleoplasmic versus cytoplasmic vitamin C concentrations
upon DHA addition. Taking into account that vitamin C
uptake and its total intracellular concentration is lower in
ATS ﬁbroblasts, one can assume a serious nucleoplasmic
impoverishment in vitamin C in ATS ﬁbroblasts.
Secondly, global methylation and hydroxymethylation of
genomic DNA was analysed by ELISA. One of the most thor-
oughly investigated epigenetic marks is the 5-methylation of
the cytosine base in dsDNA. In mammalian somatic cells,
5-mC occurs mainly in CG dinucleotides. The regulatory
eﬀects of 5-mC translating the environmental clues are well
established [30]. The oxidative modiﬁcation of 5-mC
received new interest in the last decade. Growing evidence
shows the potential role of the 5-hmC signal in gene expres-
sion, which is present mostly in gene bodies and promoter
regions in human tissues, e.g., in the brain [31], chondrocytes
[32], breast, and liver [33]. The conversion of 5-mC to
5-hmC—catalyzed by TET enzymes—is AA sensitive, as it
has been shown in cultured mouse embryonic stem cells
[34] and ﬁbroblasts [29]. The 5-mC level measured in ATS
ﬁbroblasts could not be modiﬁed by AA administration;
however, the 5-mC level in control cells could be diminished
by AA treatment. The detection of global 5-hmC levels did
not result in unequivocal data, probably due to the low
sensitivity of the ELISA method. Therefore, the 5-hmC
DHA AA
DHA
DHA
DHA AA
GLUT10
GLUT10
Reduction
Fe2+/2-oxoglutarate-dependent dioxygenases
Demethylated/hydroxylated
nucleicacids/histones
ER lumen
Nucleoplasm
NR
Cytoplasm
GLUT10
GLUT10
Figure 6: Compartmentalization-dependent eﬀect of vitamin C on epigenetic regulation. Vitamin C is transported as dehydroascorbic acid
(DHA) by GLUT10 into the endoplasmic reticulum (ER) lumen and in the nucleoplasm. Having been reduced to ascorbate (AA), it can serve
as a cofactor for Fe2+/2-oxoglutarate-dependent dioxygenases, catalyzing (among others) histone and DNA demethylation. NR,
nucleoplasmic reticulum.
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levels were estimated by a LC-MS/MS technique, which
showed that the hydroxymethylation level in the genome
of patients were lower than those in controls. Global
5-hmC levels (5-hmC/C ratios) were increased after AA
treatment in both groups, but this increase was statistically
signiﬁcant only in the control cells.
In the next step, quantitative 5-mC- and
5-hmC-enrichment analyses were carried out on candidate
genes, which code for proteins required in AA metabolism
or function or genes related to ATS pathogenesis. PPAR-γ
has a key role in the regulation of extracellular matrix for-
mation. We found lower hydroxymethylation of the
PPAR-γ gene in ﬁbroblasts from ATS patients. While in
control cells 5-hmC formation could be stimulated by
AA addition, this treatment was ineﬀective in patients’
cells. The decreased methylation level upon AA addition
in control cells conﬁrmed the observation. These results
can be ascribed to a decreased accessibility of the cofactor
to DNA demethylases.
The involvement of the epigenetic regulation of the
PPAR-γ gene is not unprecedented. TET upregulation
led to reduced DNA methylation and elevated 5-hmC for-
mation, both globally and speciﬁcally at the PPAR-γ locus
in preadipocytes, which was required for adipogenic diﬀer-
entiation [35]. Epigenetic regulation of the antiﬁbrogenic
PPAR-γ and the proﬁbrogenic TGF-β1 was observed dur-
ing wound healing [36]. Moreover, hypermethylation of
the promoter of PPAR-γ gene was signiﬁcantly associated
with ﬁbrosis in the liver [37]. Activation of PPAR-γ has been
reported to inhibit the TGF-β pathway in mesangial cells
and mesenchymal stem cells [38, 39]. These observations
can be related to the pathomechanism of ATS. Increased
TGF-β activity has also been repeatedly postulated as an
important causal factor of genetic arteriopathies [40]. Dys-
regulation of the PPAR-γ-TGF-β pathway has been
reported in ﬁbroblasts from ATS patients [41]. Indeed,
PPAR-γ activators are among the candidates for the treat-
ment of aorta aneurysms [42].
The role of vitamin C in epigenetic regulation has been
demonstrated by several studies in diﬀerent experimental
systems (for recent reviews, see [5, 43]). Ascorbate concen-
tration seems to be a rate-limiting factor in the catalytic
activity of the histone and DNA demethylases of the
Fe2+/2-oxoglutarate-dependent dioxygenase family [44].
Plasma membrane vitamin C transporters have emerged
as modulators of ascorbate-dependent epigenetic regula-
tion [45–47]. The present paper demonstrates ﬁrstly that
intracellular vitamin C transporters responsible for the
entry of AA or DHA into subcellular compartments are
also important determinants of vitamin C eﬀects. The
absence of GLUT10, a DHA transporter of the endomem-
branes, hinders vitamin C transport into the nucleoplasm
and the lumen of the ER membrane (Figure 6). A lower
AA concentration in the nucleus results in the suboptimal
functioning of Fe2+/2-oxoglutarate-dependent dioxygenases
and increased 5-mC/5-hmC ratio.
Subcellular or noncanonical scurvy has already been
reported in the ER lumen [48, 49], which was due to
the increased consumption of AA. Here, we showed that
the decreased entry could also cause AA deﬁciency in
another compartment, i.e., the nucleus, resulting in epige-
netic alterations. Further studies are needed to clarify
whether these changes signiﬁcantly contribute to the
pathogenesis of ATS or not. In any case, increasing global
DNA methylation has been reported in any tissue across
the entire life course [50]. The accelerated epigenetic
clock in ATS ﬁbroblasts may lead to premature aging
with its undesirable consequences. Furthermore,
gene-speciﬁc alterations in the methylation (e.g., of
PPAR-γ gene) can also support a more speciﬁc hypothe-
sis for the pathogenesis.
5. Conclusions
Emerging evidence suggests that vitamin C can inﬂuence
gene expression via regulating epigenetic processes. Here,
we report that decreased nuclear accumulation of ascor-
bate in GLUT10-deﬁcient ﬁbroblasts of ATS patients is
accompanied with an altered DNA hydroxymethylation
pattern both at the global level and at speciﬁc gene
regions. The ﬁndings suggest that vitamin C has an epige-
netic role in the pathomechanism of ATS and represents
the ﬁrst example for the role of intracellular vitamin C
transport in epigenetic regulation. The results suggest that
ATS can be regarded as a compartmentalization disease.
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